2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide,
decernotinib,
VX-509,
Decernotinib,
944842-54-0,
Adelatinib,
VX-509,
UNII-MZK2GP0RHK,
Decernotinib(VX-509),
VRT-831509,
VX509,
MZK2GP0RHK,
Decernotinib (VX-509),
VX 509,
AK170453,
(R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide,
(2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide,
Decernotinib [USAN:INN],
decernotinib-vx-509,
VRT 831509,
Decernotinib,VX-509,
Decernotinib (USAN/INN),
VX-509 (Decernotinib),
GTPL8309,
SCHEMBL2630387,
CHEMBL3039513,
KS-00001CYK,
DTXSID70241504,
ASUGUQWIHMTFJL-QGZVFWFLSA-N,
Decernotinib (VX-509 adelatinib),
AOB87117,
EX-A1580,
BDBM50021655,
MFCD27987896,
s7541,
ZINC96941867,
AKOS025290739,
CS-3990,
DB12566,
SB16545,
NCGC00402345-02,
(2R)-2-Methyl-2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin- 4-yl)amino)-N-(2,2,2-trifluoroethyl)butanamide,
BC600783,
Butanamide, 2-methyl-2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)-4-pyrimidinyl)amino)-N-(2,2,2-trifluoroethyl)-, (2R)-,
HY-12469,
B5929,
D10585,
(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide,
(R)-2-(2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide,
N~2~-[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]-N-(2,2,2-trifluoroethyl)-D-isovalinamide,
VJK,
Adelatinib [INN],
DecernotinibVX-509,
Decernotinib?VX-509?,
D04QWQ,
A14012,